Boehringer Ingelheim showcases its leading vaccines and services at WVPAC 2019
Boehringer Ingelheim continues to lead in hatchery vector vaccination worldwide with VAXXITEK® and NEWXXITEK®
5 September 2019
4 minute read
Boehringer Ingelheim will exhibit at the 21st
World Veterinary Poultry Association Congress (WVPAC), one of the most important global poultry exhibitions, and present its solutions for hatchery vaccination.
"This year’s theme of the conference is ‘Poultry: the value of protein for one’s health’ focusing on food safety and biosecurity which fits very well with our aspiration to create the future of poultry well-being through preventive care. We look forward to engaging with experts and opinion leaders in productive conversations at the event"
-Jérôme Baudon, Head of Poultry Business Unit, Boehringer Ingelheim. -
Leading position in hatchery vaccination thanks to vector vaccines
VAXXITEK ® HVT+IBD celebrated a milestone of over 100 billion birds vaccinated last year.
NEWXXITEK® HVT+ND, the vectored Newcastle disease technology produced by Boehringer Ingelheim protects flocks against Newcastle disease, even velogenic strains with no adverse reaction post-vaccination.
VAXXITEK® HVT+IBD+ND, the latest poultry vaccine from Boehringer Ingelheim - the trusted leader1 in IBD vector vaccine technology - has been approved2 by the USDA authorities early August 2019.
A comprehensive solution for Infectious Bronchitis vaccination
The causative agent of IB is an avian coronavirus which is able to mutate and produce new viruses, called variants. The development and licensing of new vaccines each time a new variant appears is impractical, costly and time consuming. That is why Boehringer Ingelheim offers both Mass and Variant IB vaccine for a cross-serotype protection. Hatchpak® Bioral H120 has been designed to offer a high number of doses per amp hatchery vaccination solution while Bioral H120 NeO and Gallivac IB88 NeO are available in innovative effervescent tablets for a simplified vaccination administration. Part of the protection includes the inactivated range with Gallimune and Cor-2 products.
Innovation in vaccination equipment with its Vaccination Technologies and Services
The Ovo-Jector developed by Boehringer Ingelheim is one of the most compact In-Ovo machine in the market with selective vaccination and transfer. It can selectively vaccinate up to 42,000 eggs per hour. VTS fits all hatcheries' needs designing sprayers and solutions for day-old chick injections.
“The Vaccination Technologies and Services has been identified as a strategic initiative for our poultry business and it is fully in line with our goal to provide best services to hatcheries. Vaccination equipment is an integral part of our value proposition,” said Chris Fritts, VTS Global Head, Boehringer Ingelheim.
Boehringer Ingelheim will be present at booth D4, concourse Bhiraj hall, 2nd floor.
